Clinipace's Growth Supported by New Executive Leadership and Investment in Clinical Technology
Clinipace, a global full-service contract research organization (CRO), has named industry executive John Cargill as its chief commercial officer and announces that Hampton Corley has become the company’s new vice president, business development, clinical analytics. Adding this depth of expertise to the Clinipace team supports the company’s growth as a midsized CRO that provides global, integrated solutions.
With broad CRO experience in the biotech, life science and health care sectors globally, Cargill will leverage Clinipace’s team-oriented, personal approach to work with clients who need the expertise, flexibility and comprehensive services offered by the midsized company. With leadership experience in several therapeutic areas, Cargill will develop strategic plans for clients while providing a customized and dedicated experience. He has held executive roles at several leading CROs, most recently as vice president at Covance, heading global business development for clinical analytics and strategic clinical sourcing.
Corley will focus on growing Clinipace’s suite of clinical analytics services and functional service provider (FSP) offerings, which utilize the company’s new Clarity Stack clinical technology platform. Clarity Stack technology improves interoperability of clinical trial operations by facilitating informed decision making, improving compliance and identifying issues faster.
“As we grow, we are committed to making investments that will put us in position to bring forward the best clinical development services and solutions based on client needs,” said Jason Monteleone, CEO at Clinipace. “Both John’s and Hampton’s experience in the industry will help us continue to build strong relationships and provide clients with a high level of personal service.”
For more information about Clinipace, stop by Booth 53 at the Outsourcing Clinical Trials New England meeting, Nov. 6-7, 2018.
At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005151/en/